Carl Hansen, AbCellera CEO
February 14, 2022 07:06 AM EST
FDA+
Coronavirus

As Omi­cron rages, FDA clears Eli Lil­ly/Ab­Celler­a's new an­ti­body days af­ter $720M sup­ply deal

Amber Tong

The FDA has au­tho­rized a new Covid-19 an­ti­body from Eli Lil­ly and Ab­Cellera, adding a much-need­ed weapon to the ar­se­nal fight­ing against Omi­cron.

Just days …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times